Staff

Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects

Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus SAN DIEGO and TAICANG, SUZHOU, China,...

error: Content is protected !!